Pharvaris (PHVS) Accounts Payables (2019 - 2026)
Pharvaris' (PHVS) quarterly Accounts Payables came in at $3.2 million in Q1 2026, down 28.63% YoY from $4.4 million in Q1 2025, and down 46.71% on a QoQ basis from $6.0 million in Q4 2025.
Analysis
Pharvaris (PHVS) Accounts Payables (2019 - 2026) Analysis & Trends
Pharvaris (PHVS) has 8 years of Accounts Payables data on file, last reported at $3.2 million in Q1 2026.
- Quarterly Accounts Payables fell 28.63% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 28.63% YoY) and the FY2025 annual result came in at $5.8 million, up 17.0% from the prior year.
- Accounts Payables retreated to $3.2 million in Q1 2026, from $6.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $8.6 million in Q1 2023 to a low of $3.0 million in Q3 2025.
- A 5-year average of $5.0 million and a median of $4.8 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 139.39% — and 2023, when it sank 54.1%.
- Tracing PHVS's Accounts Payables over 5 years: stood at $6.8 million in 2022, then slumped by 54.1% to $3.1 million in 2023, then jumped by 55.75% to $4.9 million in 2024, then advanced by 22.09% to $6.0 million in 2025, then slumped by 46.71% to $3.2 million in 2026.
- The last three Accounts Payables figures came in at $3.2 million (Q1 2026), $6.0 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | 3,247.29 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,247.29 Bn |
| Mar 31, 2026 | 3,172.53 Bn |
| Dec 31, 2025 | 5,953.14 Bn |
| Sep 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 4.45 Mn |
| Dec 31, 2024 | 4,875.89 Bn |
| Sep 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 6.04 Mn |
| Dec 31, 2023 | 3,130.69 Bn |
| Sep 30, 2023 | 4.83 Mn |
| Jun 30, 2023 | 5,746.92 Bn |
| Mar 31, 2023 | 8.62 Mn |
| Dec 31, 2022 | 6,820.44 Bn |
| Sep 30, 2022 | 7.15 Mn |
| Jun 30, 2022 | 4.45 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | 2,849.14 Bn |
| Sep 30, 2021 | 4.54 Mn |